A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy

Juanita Crook; Nikitha Moideen; Greg Arbour; Felipe Castro; Cynthia Araujo; Deidre Batchelar; Ross Halperin; Michelle Hilts; David Kim; David Petrik; Jim Rose; J C Cheng; Francois Bachand

doi:10.1016/j.ijrobp.2024.02.064

A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy

Int J Radiat Oncol Biol Phys. 2024 Mar 16:S0360-3016(24)00381-X. doi: 10.1016/j.ijrobp.2024.02.064. Online ahead of print.

Authors

Affiliations

¹ Division of Radiation Oncology, Univeristy of British Columbia, Vancouver, British Columbia, Canada. Electronic address: jcrook@bccancer.bc.ca.
² Radiation Oncology, BCCancer, Kelowna, British Columbia, Canada.
³ Department of Statistics, University of British Columbia, Vancouver, British Columbia, Canada.
⁴ Medical Physics, BCCancer, Kelowna, British Columbia, Canada.
⁵ Radiation Oncology, BCCancer, Abbottsford, British Columbia, Canada.

PMID: 38493901
DOI: 10.1016/j.ijrobp.2024.02.064

Abstract

Purpose: To compare health-related quality of life (QoL) in urinary, bowel, and sexual domains after combined external beam radiation therapy (EBRT) and either low-dose rate (LDR) or high-dose rate (HDR) prostate brachytherapy (BT).

Methods and materials: Eligible men with intermediate or high-risk prostate cancer treated with combined pelvic EBRT and BT were randomly assigned to either HDR (15 Gy) or LDR (110 Gy) boost. International Prostate Symptom Score, Index of Erectile Function, and Expanded Prostate Cancer Composite were collected at baseline, 1, 3, 6, and 12 months, every 6 months to 3 years and then annually along with prostate-specific antigen/testosterone. Fisher's exact test compared categorical variables and the Mann-Whitney U test Expanded Prostate Cancer Index Composite (EPIC) domain scores.

Results: From January 2014 to December 2019, a random number generator assigned 195 men: 108 to HDR and 87 to LDR. Median age was 71 years. Risk group was high in 57% and unfavorable intermediate in 43%. Androgen deprivation (used in 74%) began with 3 months neoadjuvant and continued for median 12 months. Baseline EPIC scores were similar for the LDR/HDR cohorts: 89 and 88 respectively for Genito-urinary; 92 and 93 for Gastro-intestinal. EPIC urinary scores decreased at 1 month for HDR but recovered promptly to a steady state by 6 months. LDR scores reached a nadir at 3 months with slow recovery to 18 months, after which urinary QoL was similar for HDR and LDR. Bowel QOL scores fell in both cohorts reaching respective nadirs at 12 months. HDR patients recovered close to baseline and maintained higher scores than LDR patients to 5 years. The decline for LDR patients remained more than the minimum clinically important difference out to 5 years.

Conclusions: The patient experience for combined EBRT and prostate BT is improved with HDR BT. Urinary QoL improves over time to be equivalent between the 2 modalities after 18 months, but LDR patients report lasting bowel symptoms.